Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Recursion Pharmaceuticals operates an AI-driven drug discovery platform combining high-throughput biology, automation, and machine learning to identify novel therapeutic candidates across multiple disease areas. The company generates revenue primarily through strategic partnerships (Roche, Bayer collaborations worth $50M+ upfront) while advancing a proprietary pipeline of 5+ clinical-stage programs in oncology and rare diseases. Stock performance is driven by clinical trial readouts, partnership announcements, and AI platform validation milestones rather than near-term profitability.
Recursion monetizes its proprietary OS (operating system for drug discovery) through upfront payments, research funding, milestone payments, and royalties from pharmaceutical partners who gain access to AI-generated insights and novel targets. The platform screens billions of cellular perturbations to identify disease-modifying compounds, reducing traditional R&D timelines from 5-7 years to 2-3 years for lead identification. Pricing power derives from demonstrating superior hit rates and faster cycle times versus traditional high-throughput screening, with partnerships structured as multi-year, multi-target deals providing recurring revenue visibility. The company retains full economics on proprietary pipeline assets targeting high unmet need indications where it can capture 100% of value.
Clinical trial data readouts from lead programs (REC-994 in cerebral cavernous malformation, REC-4881 in familial adenomatous polyposis) - positive Phase 2 data can drive 30-50% single-day moves
New pharmaceutical partnership announcements with upfront payments exceeding $20M and validation of platform economics
AI platform capability demonstrations showing improved prediction accuracy or novel target identification versus traditional methods
FDA regulatory milestones including IND clearances for new pipeline programs and breakthrough therapy designations
Quarterly cash burn rate and runway updates - company had approximately $400M cash as of recent periods with ~$100M quarterly burn
AI/ML platform validation risk - if proprietary algorithms fail to demonstrate superior clinical success rates versus traditional drug discovery methods over 5-10 year timeframe, partnership economics and competitive differentiation erode significantly
Regulatory uncertainty around AI-discovered therapeutics as FDA develops evolving guidance on algorithm transparency, training data requirements, and validation standards for computationally-designed molecules
Technological disruption from competitors (Insitro, Exscientia, BenevolentAI) or large pharma in-house AI capabilities reducing willingness to pay for external platforms
Large pharmaceutical companies building internal AI drug discovery capabilities (Amgen, Novartis, AstraZeneca investments exceeding $100M annually) could reduce demand for external partnerships
Well-funded competitors with similar AI-biology platforms competing for same partnership dollars and clinical validation milestones, potentially compressing deal economics
Traditional CROs and drug discovery service providers adding AI capabilities at lower price points for routine screening work
High cash burn rate of approximately $100M per quarter creates ongoing dilution risk if equity markets remain unfavorable - current runway extends into 2027 but requires additional financing before multiple programs reach commercialization
Minimal debt (0.08 D/E ratio) limits financial leverage risk but also means future capital raises will be equity-dilutive to existing shareholders
Partnership revenue concentration risk with Roche and Bayer representing majority of near-term cash flows - loss of key partnership could accelerate cash burn
low - Drug discovery and development spending by large pharmaceutical partners is largely acyclical and driven by patent cliffs, pipeline gaps, and long-term R&D budgets rather than GDP fluctuations. Biotech funding environment shows some correlation to risk appetite during severe recessions, but established partnerships with Roche and Bayer provide revenue stability. Clinical trial execution timelines are unaffected by economic cycles.
Rising interest rates create moderate headwinds through two channels: (1) higher discount rates compress NPV of distant cash flows from early-stage pipeline assets, disproportionately impacting pre-revenue biotech valuations and driving multiple compression from 30x+ sales to sub-20x during rate hiking cycles, and (2) tighter financial conditions reduce availability of follow-on equity financing and increase dilution risk when raising capital to fund clinical programs. However, the company's strong balance sheet (4.6x current ratio) and partnership revenue mitigate near-term refinancing risk. Rate cuts would provide valuation tailwind by improving risk asset appetite and biotech sector multiples.
Minimal direct credit exposure as the business model does not involve lending or credit-sensitive end markets. Indirect exposure exists through pharmaceutical partner financial health, but Roche and Bayer maintain investment-grade credit ratings. Tightening credit conditions could impact smaller biotech partners' ability to fund collaborations, but this represents <10% of revenue mix.
growth - The stock attracts speculative growth investors and biotech specialists willing to accept 5-10 year investment horizons and binary clinical risk in exchange for potential 5-10x returns if platform validates and multiple programs reach commercialization. Negative earnings and cash flow eliminate value and income investors. The AI-driven approach appeals to technology crossover funds seeking healthcare exposure. Institutional ownership skewed toward healthcare-focused funds and venture capital firms from earlier funding rounds. High volatility (implied vol typically 60-80%) and -67% one-year return reflect risk-on/risk-off sentiment swings.
high - Historical beta exceeds 1.5x relative to biotech indices with frequent 15-25% single-day moves on clinical data or partnership news. Stock exhibits classic pre-revenue biotech volatility profile with sentiment-driven trading overwhelming fundamentals. Recent 67% decline over 12 months reflects broader biotech sector weakness, rising rates compressing growth multiples, and lack of near-term clinical catalysts. Options market prices 60-70% annualized volatility reflecting binary event risk from trial readouts.
